Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 250

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma

Open access
Maurizi, M, Almadori, G, Ferrandina, G, Distefano, M, Romanini, ME, Cadoni, G, Benedetti-Panici, P, Paludetti, G, Scambia, G, Mancuso, S · 1996 · British Journal of Cancer

Abstract

Epidermal growth factor receptor (EGFR) content was determined by a radioligand receptor assay in 140 primary laryngeal squamous cell carcinomas (median value of 8.4 fmol mg-1 protein, range 0-169.9 fmol mg-1 protein). Cox univariate regression analysis using EGFR as a continuous variable showed that EGFR levels are directly associated with the risk of death (chi 2 = 14.56, P-value = 0.0001) and relapse (chi 2 = 7.77, P-value = 0.0053). A significant relationship between EGFR status and survival was observed at the different arbitrary cut-off values chosen (8, 16 and 20 fmol mg-1 protein). The cut-off value of 20 fmol mg-1 protein was the best prognostic discriminator. In fact, the 5 year survival was 81% for patients with EGFR- tumours compared with 25% for patients with EGFR+ tumours (P < 0.0001). The 5 year relapse-free survival was 77% for patients with EGFR- tumours compared with 24% for patients with EGFR+ tumours (P < 0.010). When clinicopathological parameters and EGFR status were examined in the multivariate analysis, T classification and EGFR status retained an independent prognostic value. In this study we demonstrated that high EGFR levels single out patients with poor prognosis in laryngeal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.1996.525

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

    Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806 · cited 1×

    “…on drugs targeted directly against EGFR activity, such as anti- EGFR monoclonal antibodies and the specific inhibitor of the EGFR tyrosine kinase, which inhibit the growth of cancer ceRls in vitro and in vivo (Moreshige et al., 1991; Kurachi et al., 1991; Schnurch et al., 1994; Fry et al., 1994).”
    Background

Cited by

See all 250

Metadata

Authors
Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M., Cadoni, G., Benedetti-Panici, P., Paludetti, G., Scambia, G., & Mancuso, S.
Venue
British Journal of Cancer
Published
1996-10
Volume
74
Issue
8
Pages
1253-1257
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2020600496
Cited by
250
References
1
FWCI
6.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.